Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 396-403

  Harder, Sebastian ^a   Parisius, Jeannine ^a   Picard Willems, Bettina ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Direct FXa inhibitors; Prothrombinase induced clotting time; Rivaroxaban; Russells Viper Venom

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; OXAZOLIDINONE DERIVATIVE; RIVAROXABAN;

ARTICLE; BIOASSAY; BLOOD; BLOOD CLOTTING TIME; CALCIFICATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MONITORING; HUMAN; INCUBATION TIME; INHIBITION KINETICS; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; PROTHROMBINASE INDUCED CLOTTING TIME;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BIOLOGICAL ASSAY; BLOOD COAGULATION TESTS; CATTLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA; HUMANS; INHIBITORY CONCENTRATION 50; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; THROMBOPLASTIN;

EID: 55549103684     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.05.010     Document Type: Article

References (20)

1. Samama M.M. Synthetic direct and indirect factor Xa inhibitors. Thrombosis Res 106 (2002) V267-V273
2. Kubitza D., Becka M., Voith B., Zuehlsdorf M., and Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 (2005) 412-421
3. Paccaly A., Ozoux M.L., Chu V., Simcox K., Marks V., Freyburger G., Sibille M., and Shukla U. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost 94 (2005) 1156-1163
4. Alexander J.H., Yang H., Becker R.C., Kodama K., Goodman S., Dyke C.K., Kleiman N.S., Hochman J.S., Berger P.B., Cohen E.A., Lincoff A.M., Burton J.R., Bovill E.G., Kawai C., Armstrong P.W., and Harrington R.A. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 3 (2005) 439-447
5. Fisher W.D., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Gent M., Haas S., Homering M., Huisman M.V., Kakkar A.K., Kälebo P., Kwong L.M., Misselwitz F., and Turpie A.G. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 97 (2007) 931-937
6. Harder S., Klinkhardt U., and Alvarez J.M. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 43 (2004) 963-981
7. Calatzis A., Harder S., and Wilmer M. Monitoring of direct FXa inhibitors using the prothrombinase induced clotting test (PiCT). Hämostaseologie 26 (2006) 102
8. Calatzis A., Spannagl M., Gempeler-Messina P., Kolde H.J., Schramm W., and Haas S. The prothombinase-induced clotting test (PiCT®): A new technique for the monitoring of anticoagulants. Haemostasis 30 (2000) 172-174
9. Product Information Pefakit PiCT, available at http://www.pentapharm.com/sw207.asp (last access 2.2.2008).
10. Fenyvesi T., Jorg I., and Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 32 (2002) 174-179
11. Graff J., Picard-Willems N., and Harder S. Monitoring effects of direct FXa-inhibitors with a new One-Step Prothrombinase-induced Clotting Time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux, and DX 9065a. Int J Clin Pharm Ther 45 (2007) 234
12. Herbert J.M., Bernat A., Dol F., Hérault J.P., Crépon B., and Lormeau J.C. DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 276 (1996) 1030-1038
13. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.H., Reinemer P., and Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48 (2005) 5900-5908
14. Samama M.M., Gerotziafas G.T., Elalamy I., Horellou M.H., and Conard J. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 32 (2002) 218-224
15. Greaves M. Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 87 (2002) 163-164
16. Raivio P., Kuitunen A., Petäjä J., Ilveskero S., and Lassila R. Monitoring high-dose heparinization during cardiopulmonary by-pass-a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Thromb Haemost 99 (2008) 427-434
17. Graff J., Hentig N.v., Misselwitz F., Kubitza D., Becka M., Breddin H.K., and Harder S. Effects of the oral, direct Factor Xa-inhibitor rivaroxaban (BAY 59-7939) on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharm 47 (2007) 1398-1407
18. Turpie A.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., Kälebo P., Misselwitz F., and Gent M. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3 (2005) 2479-2486
19. Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., Misselwitz F., and Kälebo P. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 (2006) 121-128
20. Mueck W., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Fisher W.D., Gent M., Haas S., Huisman M.V., Kakkar A.K., Kälebo P., Kwong L.M., Misselwitz F., and Turpie A.G. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47 (2008) 203-216